Business

MASS. MOVERS

Amag results expected to come up short

ISTOCKPHOTO.COM

Advertisement

Amag Pharmaceuticals Inc. slumped on preliminary fourth-quarter revenue of between $14.3 million and $15 million, lower than the $16 million analysts had estimated. The Lexington company put itself up for sale late last year after lackluster revenue for its anemia drug and a failed merger bid. It received approval for Feraheme from Canadian regulators in December. Amag said it expects fourth-quarter operating costs and expenses of $38 million to $43 million, including restructuring costs and a $2 million termination fee to Allos Therapeutics.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com